theranostics Feb 17, 2023 Blue Earth Diagnostics Produces New Data Supporting FDA Approval of Prostate Cancer Imaging Agent Feb 14, 2023 Fusion Pharmaceuticals to Acquire Prostate Cancer Radiopharmaceutical Program From RadioMedix Feb 8, 2023 Actinium Pharmaceuticals, NCI Ink Research Agreement on Targeted Radiopharmaceutical Feb 6, 2023 Isoray, Viewpoint Molecular Targeting Complete Merger to Advance Targeted Radiopharmaceuticals Feb 2, 2023 Ratio Therapeutics Raises $20M in Series A Financing Feb 1, 2023 Novartis' Oncology Drugs See Solid Growth in Q4 2022 Premium Jan 23, 2023 Viewpoint Molecular Targeting Treats First Neuroendocrine Cancer Patients With Radiopharmaceutical Dec 13, 2022 Novartis' Pluvicto Approved in Europe for PSMA-Positive Castration-Resistant Prostate Cancer Dec 5, 2022 Novartis to Seek Pluvicto Approval in Another Advanced PSMA-Positive Prostate Cancer Setting Dec 1, 2022 Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers Nov 29, 2022 ICPO Foundation, PreMIT Collaborate to Establish Theranostic Centers Nov 21, 2022 Clarity Pharmaceuticals to Evaluate GRPr-Targeting Radiopharmaceutical in mCRPC Trial Nov 14, 2022 Lantheus Licenses Two Late-Stage Radiopharmaceutical Candidates From Point Biopharma Nov 10, 2022 ImaginAb, Parthenon Ink Licensing Deal to Use PET Imaging in Immunotherapy Trial Oct 28, 2022 In Brief This Week: Caris Life Sciences, Radiopharm Theranostics, Tempus Oct 25, 2022 ImaginAb Doses First Patient in Study of CD8-Targeted PET Imaging Agent in Australia Oct 25, 2022 Nihon Medi-Physics to Begin Phase I Trial of Theranostic Antibody NMK89 Oct 20, 2022 GE Healthcare Educating Docs on Guidelines-Backed Use of Imaging Agent for ER-Positive Breast Cancer Premium Oct 19, 2022 Blue Earth Diagnostics, Siemens Healthineers Partner on Prostate Cancer Theranostics, PET Imaging Oct 14, 2022 EMA's CHMP Recommends Novartis' Pluvicto for PSMA-Positive mCRPC Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors